Narjust Florez: Sarah Waliany on mechanisms of resistance to first-line vs. later-line Alectinib for ALK and NSCLC
Narjust Florez, Thoracic Medical Oncologist at the Dana-Farber Brigham Cancer Center, shared a post on X:
“Sarah Waliany is one of our abstract award winners for the DF/HCC lung cancer symposium – she discussed mechanisms of resistance to first-line vs. later-line Alectinib for ALK and NSCLC.”
Narjust Florez is the Associate Director of the Cancer Care Equity Program and a Thoracic Medical Oncologist at the Dana-Farber Brigham Cancer Center. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer. In addition, Dr. Florez founded the Florez Lab in 2019. The laboratory focuses on lung cancer, social justice issues in medicine, and medical education.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023